Physician profile
Ellen Regal
NPI 1912427881
$4,789.39
in general payments reported to CMS, 2019-2025
33 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $207 · 2022: $340 · 2023: $1,459 · 2024: $1,228 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,242.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,112.15 | 2021-2025 | |
| Glaxosmithkline, LLC. | $717.58 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $444.37 | 2022-2025 | |
| Novo Nordisk INC | $437.66 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $253.35 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Exact Sciences Corporation | $244.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $223.95 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $223.80 | 2022-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $145.34 | 2023-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $137.80 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $122.48 | 2024-2025 | |
| Amgen INC. | $110.96 | 2023-2024 | Prolia, Evenity, Repatha |
| E.R. Squibb & Sons, L.L.C. | $106.44 | 2022-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.27 | 2023-2025 | Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.05 | 2022-2025 | Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $36.83 | 2024 | Apollo Esg System |
| Verona Pharma, INC. | $35.47 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $34.56 | 2021-2025 | Gardasil 9, Capvaxive |
| Ironwood Pharmaceuticals, INC | $24.99 | 2023 | Linzess |
| Biohaven Pharmaceutical Holding Company LTD. | $24.65 | 2022 | |
| Idorsia Pharmaceuticals US INC | $22.66 | 2023 | Quviviq |
| Ars Pharmaceuticals Operations, INC. | $20.89 | 2025 | Neffy |
| Sunovion Pharmaceuticals INC. | $18.71 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.56 | 2021 | |
| Sanofi Pasteur INC. | $17.50 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.98 | 2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.95 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $16.59 | 2024 | Heplisav-B |
| Optinose US, INC. | $16.43 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $15.44 | 2021 | |
| Dexcom, INC. | $14.81 | 2025 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $14.79 | 2023 | Edarbyclor |
| Renalytix Ai, INC. | $12.90 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Regal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.